Lab
Doctors General Laboratory Corp
Doctors General Laboratory Corp was paid $8.10M by Medicaid between Jan 2018 and Dec 2024, across 70 billing codes. Its largest line is U0004, 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r — 36% of everything it billed.
33Billing provider infoDOCTORS GENERAL LABORATORY CORP
CLARENDON HILLS, IL 60514
CLARENDON HILLS, IL 60514
33aNPI1851392617assigned 08/02/2005
33bProvider typeClinical Medical Laboratory
28Total paid$8.10M
24GClaims224,283
24DCodes billed70
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in Illinois
Rank by total paid#22 of 235
Median peer was paid$123K
This provider vs. median66×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 13,995 | $107K | |
| 2019 | 16,423 | $714K | |
| 2020 | 35,494 | $2.06M | |
| 2021 | 34,299 | $1.34M | |
| 2022 | 75,663 | $2.47M | |
| 2023 | 39,932 | $1.28M | |
| 2024incomplete | 8,477 | $128K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | 36% | 41,070 | 19,528 | $2.90M |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | 22% | 15,921 | 14,023 | $1.75M |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 12% | 25,035 | 21,908 | $1000K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 6.0% | 26,804 | 15,025 | $485K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 5.4% | 22,452 | 13,768 | $438K |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | 5.0% | 11,223 | 5,831 | $405K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | 3.3% | 3,643 | 3,106 | $265K |
| 80299 | 2.1% | 2,065 | 1,628 | $167K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 686 | 486 | $78K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 828 | 304 | $77K |
| G2024 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]) from an individual in a snf or by a laboratory on behalf of a hha, any specimen source | <1% | 3,385 | 1,031 | $74K |
| 80053 | Comprehensive metabolic panel | <1% | 9,443 | 7,211 | $68K |
58 more codes
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 10,462 | $47K |
| 86141 | <1% | 2,586 | $35K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 3,286 | $33K |
| 87505 | <1% | 263 | $22K | |
| P9604 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge | <1% | 4,452 | $18K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 2,285 | $15K |
| 87482 | <1% | 362 | $13K | |
| 80061 | Lipid panel | <1% | 3,382 | $12K |
| 82533 | <1% | 1,111 | $12K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 364 | $11K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 353 | $11K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 2,708 | $11K |
| 82607 | <1% | 1,470 | $10K | |
| 87640 | <1% | 334 | $10K | |
| 85651 | <1% | 2,489 | $9K | |
| 86592 | <1% | 2,696 | $9K | |
| 87652 | <1% | 358 | $9K | |
| 83735 | <1% | 1,753 | $9K | |
| 84436 | <1% | 1,413 | $8K | |
| 83540 | <1% | 1,753 | $8K | |
| 87500 | <1% | 351 | $7K | |
| 84479 | <1% | 1,295 | $7K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,030 | $6K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 292 | $6K |
| 81007 | <1% | 1,210 | $5K | |
| 87512 | <1% | 182 | $5K | |
| 85610 | <1% | 1,543 | $5K | |
| 81000 | <1% | 2,655 | $4K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 628 | $4K |
| 84466 | <1% | 803 | $4K | |
| 86038 | <1% | 281 | $4K | |
| 83721 | <1% | 977 | $3K | |
| 82746 | <1% | 558 | $3K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 80 | $3K |
| 85027 | <1% | 735 | $3K | |
| 87634 | <1% | 71 | $2K | |
| 86060 | <1% | 204 | $1K | |
| 87186 | <1% | 230 | $1K | |
| 86677 | <1% | 80 | $983.60 | |
| 82728 | <1% | 357 | $697.71 | |
| 84550 | <1% | 248 | $650.80 | |
| 86318 | <1% | 22 | $646.51 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 1,895 | $575.45 |
| 84439 | <1% | 302 | $519.84 | |
| 84153 | <1% | 38 | $419.76 | |
| 83655 | <1% | 31 | $337.59 | |
| 82043 | <1% | 136 | $334.49 | |
| 87077 | <1% | 163 | $300.66 | |
| 83718 | <1% | 52 | $275.76 | |
| G0471 | Collection of venous blood by venipuncture or urine sample by catheterization from an individual in a skilled nursing facility (snf) or by a laboratory on behalf of a home health agency (hha) | <1% | 343 | $234.62 |
| 84100 | <1% | 114 | $217.73 | |
| 83880 | <1% | 42 | $185.57 | |
| 86140 | <1% | 32 | $140.28 | |
| P9603 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated miles actually travelled | <1% | 749 | $63.00 |
| 84134 | <1% | 56 | $5.43 | |
| 80076 | <1% | 34 | $4.79 | |
| 84481 | 0% | 15 | $0.00 | |
| 87088 | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialPATEL, MAHENDRA (PRESIDENT)
| Provider | Location | Paid |
|---|---|---|
| North Valley G.I. Consultants | Simi Valley, CA | $795K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.